One year in review
One year in review 2021: Sjögren’s syndrome
G. Cafaro1, R. Bursi2, L.G. Chatzis3, G. Fulvio4, F. Ferro5, E. Bartoloni6, C. Baldini7
- Rheumatology Unit, Department of Medicine and Surgery, University of Perugia, Italy.
- Rheumatology Unit, Department of Medicine and Surgery, University of Perugia, Italy.
- Department of Pathophysiology, Athens School of Medicine, National and Kapodistrian University of Athens, and Institute for Autoimmune Systemic and Neurological Diseases, Athens, Greece.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Rheumatology Unit, Department of Medicine and Surgery, University of Perugia, Italy.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy. chiara.baldini74@gmail.com
CER15298
2021 Vol.39, N°6 ,Suppl.133
PI 0003, PF 0013
One year in review
Free to view
(click on article PDF icon to read the article)
PMID: 34874834 [PubMed]
Received: 02/11/2021
Accepted : 17/11/2021
In Press: 01/12/2021
Published: 15/12/2021
Abstract
Sjögren’s syndrome (SS) is a multifactorial systemic autoimmune disease of unknown aetiology characterised by a wide spectrum of different clinical manifestations and scattered complications. Recently, great efforts have been made to elucidate mechanisms involved in the pathogenesis of the disease in order to identify exploitable therapeutic targets in SS. Similarly, novel insights have enabled to better define disease phenotypes and different outcomes. Ultimately, the discovery of new potential therapeutic targets and a better stratification of patients are paving new avenues for novel treatment options and treat-to-target therapeutic approach. In this review, we will provide a critical digest of the recent literature published in 2020 on SS pathogenesis, clinical manifestations and novel treatment options.
